{
    "paper_id": "0a07a1fa3f3cabdc95363d76a547a83340602710",
    "metadata": {
        "title": "Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure (PRO-CARF) Protocol",
        "authors": [
            {
                "first": "Antonio",
                "middle": [
                    "Alcalde"
                ],
                "last": "Guadalajara",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jalisco",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Coronavirus-19 disease (COVID-19) is characterized by a rapid progression to respiratory failure after symptom onset. Most patients have criteria for acute respiratory distress syndrome (ARDS), consisting of acute radiographic infiltrates, hypoxemia, and lung edema of non-cardiac or fluid overload origin (2) . However, many patients present with a mismatch between severity of hypoxemia and preserved lung mechanics. Therefore, ventilation-perfusion mismatch could predominate, which implies less alveolar collapse than expected, and response to regular therapies for ARDS may not be similar (3) .",
            "cite_spans": [
                {
                    "start": 306,
                    "end": 309,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 594,
                    "end": 597,
                    "text": "(3)",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Despite general mortality of COVID-19 is less than 5%, it can reach up to 62% in critically-ill patients and even higher in patients with mechanical ventilation (4) .",
            "cite_spans": [
                {
                    "start": 161,
                    "end": 164,
                    "text": "(4)",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "A still underused therapy but with proven benefit in patients with ARDS, is the prone positioning therapy, consisting of prone positioning of the patients everyday for prolonged periods, at least of 16 h, however it is only proven in mechanically ventilated patients (5) .",
            "cite_spans": [
                {
                    "start": 267,
                    "end": 270,
                    "text": "(5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "There are scarce data regarding prone positioning in awake patients before COVI-19 pandemic. A retrospective study of 15 patients, showed this therapy combined with non-invasive mechanical ventilation significantly improved oxygenation, however this improvement was transient, as oxygenation returned to baseline at 6 h after prone sessions. There was not adverse events (6) .",
            "cite_spans": [
                {
                    "start": 371,
                    "end": 374,
                    "text": "(6)",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Another preceding study from china was published in 2019, this was a prospective observational trial which included 20 patients with moderate to severe ARDS. Authors found that prone positioning combined with oxygen through highflow nasal cannula or non-invasive mechanical ventilation, improved significantly the pO2/FIO2 ratio, and half of the patients avoided intubation. However, according to the design of the study and low sample size, this can only be taken as hypothesis-generating data (7).",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Regarding to prone positioning in COVID-19 patients, there are two observational reports, one of them with 24 (8) and the other with 15 patients (9), and only found a non-sustained improvement in oxygenation, and both had a short time to follow-up. The largest trial so far, is a feasibility prospective cohort (10), which included 56 patients, and also showed an improvement in pO2/FiO2 ratio, with an increase of 50% after a prone session of 3 hours, the pO2/FiO2 ratio returned to baseline levels in half of the patients; moreover, intubation rate was not different between patients considered as responders (increase in pO2/FiO2 ratio) and non-responders. Therefore the question if this therapy can lower the requirement of mechanical ventilation is still open.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Although prone positioning is a relatively safe therapy, it is not a standard of care and is only recommended for intubated patients with moderate to severe ARDS according to guidelines (11). Therefore, we propose this randomized controlled trial, as the potential benefit is high, and it could help to optimize resource utilization in patients with this COVID-19, as we foresee the maximal peak of the pandemic at our region is still far from now.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "The primary outcome will be intubation rate for mechanical ventilation at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary Objective"
        },
        {
            "text": "The secondary outcomes will be:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "1. Total hours of prone position at day, < at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "2. All laboratory variables recorded from admission to discharge.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "3. Lung ultrasound (LUS) score at admission to COVID-unit 4. Total number of prone sessions at day, at 28 days. 5. Hours of the longest prone session each day, at 28 days. 6. Change in oxygenation 1-hour after first prone session. 7. Change in the ROX-index 1-hour after first prone session. 8. Total days of prone positioning therapy, at 28 days. 9. Adverse effects of prone positioning therapy (ulceration, back pain, intravenous lines dislodgement), at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "10. Mechanical ventilation days, at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "11. Intensive care unit length of stay, at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "12. Hospital length of stay, at 28 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary objectives"
        },
        {
            "text": "This is a multi-center, parallel, superiority, open label, randomized controlled trial, registered with ClinicalTrials.gov (NCT04477655). It will be approved by the Ethic Committees of both participant hospitals. And informed consent will be obtained from all patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods"
        },
        {
            "text": "-Regardless of diagnosis of acute respiratory distress syndrome, all adult patients (<18 y) patients with confirmed COVID-19 by PCR and respiratory distress will be included.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion criteria"
        },
        {
            "text": "-Requirement of a fraction of inspired oxygen (FiO2) \u226530% through high-flow nasal cannula (HFNC) to maintain a capillary saturation of \u226590%. -Do-not-resuscitate or do-not-intubate order -Refusal or disability of the patient to enroll in the study",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion criteria"
        },
        {
            "text": "All patients admitted with COVID-19 to intermediate and/or intensive care unit at participating hospitals (any oxygen requirement) will be screened at two academic hospitals (Hospital Civil de Guadalajara and Hospital General de Occidente, Guadalajara, Jalisco, M\u00e9xico), and patients with requirement of HFNC with FiO2 \u226530%",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment"
        },
        {
            "text": "will be approach to participate by on-site critical care physicians. In case of absence of exclusion criteria, written informed consent will be obtained before randomization.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment"
        },
        {
            "text": "Patients of the control group will be treated with oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of 92%-95%. Prone positioning will be allowed as a rescue therapy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "Patients of the experimental group will be also treated with oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of 92%-95%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "Staff intensivist will monitor adherence to protocol and patient's status of both groups on a 24/7 basis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "The prone positioning failure criteria will be: -Worsening respiratory failure, defined as RR \u226540 /min and/or muscle fatigue -Intolerance for any reason referred by the patient.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "-Requirement of vasopressor to maintain MAP \u226565 mmHg -Altered mental status",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures (arms):"
        },
        {
            "text": "The decision for withhold prone positioning and proceed to endotracheal intubation will be left at the discretion of the attending intensivist. (see figure 1 ) HFNC therapy will be initiated at 40 L/min and 37 \u00baC according to patient comfort and tolerance (Vapotherm, Precision flow, Exeter, New Hampshire), with FiO2 titrated to a capillary saturation \u226592%, and will be continuously delivered until stopping criteria are met. The primary criteria for stopping the prone positioning therapy will be a requirement of a FiO2 \u226440% to maintain a capillary saturation \u226590% AND a persistent ROX index of >4.87 for at least 2 hours after the last prone session.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 149,
                    "end": 157,
                    "text": "figure 1",
                    "ref_id": null
                }
            ],
            "section": "Procedures (arms):"
        },
        {
            "text": "Patients will be randomly allocated to either prone positioning or control group at 1:1 ratio. Such randomization will be stratified by center with permuted blocks and length of 4; numbers will be generated by computer and patients will be sequentially numbered. Investigators assistants will recruit patients, will assign allocation groups, and will obtain informed consent from participants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Randomization and data monitoring"
        },
        {
            "text": "Due to logistic reasons and the nature of the intervention, only investigators and data analysts will be blinded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Blinding"
        },
        {
            "text": "A steering local committee will monitor the trial, with assessment of inputs to database for consistence and the presence of missing data. Study coordinators at both centers will verify accuracy of database inputs. On-site investigators at each center are responsible for adherence to the protocol, and filling paper and electronic case-report forms (see appendix). All investigators will be blinded regarding patient allocation and outcome measures until database unlock. All personal data will be coded and deidentified, and paper CRF will be stored for at least 5 years into locked cabinets at each center.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Management of data"
        },
        {
            "text": "This trial is expected to initiate on May and completion is estimated in December 30th.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Management of data"
        },
        {
            "text": "As this study includes only hospitalized patients, lost to follow-up is not expected, however, all analysis will be performed on an intention-to-treat basis in the case of protocol violations.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Management of data"
        },
        {
            "text": "Data monitoring committee will be composed of all investigators, and they will be responsible for data monitoring at the primary level, whereas the local IRB will monitor the overall conduct of the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Management of data"
        },
        {
            "text": "All potential adverse effects are expected to be non-serious (ulceration, back pain, intravenous lines dislodgment), however, all related adverse effects will be documented for each patient, and all investigators will be notified monthly. In case of serious harm, the monitoring committee will discuss the termination of the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse effects"
        },
        {
            "text": "With an intubation rate of 60% according to a recent report from some American centers , and assuming a decrease to 40% to be clinically relevant, we calculated at least a total of 96 patients per group, for a beta of 0.2, and alpha of 0.5. Therefore, we plan to recruit 200 patients, accounting for minimal losses to follow up. There are no plan for interim analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample size"
        },
        {
            "text": "Categorical variables are presented as numbers and percentages, and comparison between groups will be performed with the chi-square test or the Fisher's exact test as appropriate. Continuous variables are given as means (\u00b1SD) or medians (inter-quartile ranges) and will be compared using the Student's t test or the Mann-Whitney test, according to Shapiro-Wilk test for distribution. For comparison between variables recorded at multiple time points, ANOVA for repeated measures will be used. The comparison between groups for cumulative probability of avoiding endotracheal intubation will be performed with Kaplan-Meier analysis and log-rank test. Analysis with ROC curve will be performed with prone positioning hours/day, taking endotracheal intubation as an endpoint. All tests will be performed at two-tails and a p value <0.05 will be considered as significant. All statistical analysis and graphics will be performed with MedCalc statistical software (Ostend, Belgium).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Analysis"
        },
        {
            "text": "This study will initiate immediately after the approval from the institutional review boards at each hospital.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics approval"
        },
        {
            "text": "One of the investigators (GAA) will be responsible for documentation of the protocol amendments, and for process the approval from the IRB.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol amendments"
        },
        {
            "text": "All authors hereby declare that they not have any conflict of interest",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflict of interests"
        },
        {
            "text": "Only investigators and IRB audit tema will have access to data.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Access to data"
        },
        {
            "text": "Relevant clinical data obtained in this study will be published in peer-review journals of critical/respiratory care, without disclosing any individual patient data. All the investigators will be authors in those final publications. Patient level data, could be shared to abroad investigators on a reasonable request, after data sharing agreement is granted from the local IRB. Sharing of statistical code is not planed. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dissemination policy"
        },
        {
            "text": "Initiate oxygen with nonrebreathing mask",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Respiratory symptoms & COVID+ (PCR/CT) y capillary saturation <92%"
        },
        {
            "text": "Endotracheal intubation for all patients whose capillary saturation is \u226480% despite 100% inspired oxygen and maximal tolerated flow, as well as patients with CO2 retention, progressive clinical worsening in respiratory distress, anxiety or altered mental status, regardless the magnitude of oxygen support.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Control group (supine) Intervention group (prone)"
        },
        {
            "text": "Este Formulario de Consentimiento Informado se dirige a hombres y mujeres que son atendidos en los hospitales mencionados en el encabezado, y que se les invita a participar en la investigaci\u00f3n cl\u00ednica Uso de posici\u00f3n prona en pacientes despiertos con s\u00edndrome de dificultad respiratoria aguda moderado/ severo y COVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Nombre del Investigador Principal: Dr. Miguel \u00c1ngel Ibarra Estrada"
        },
        {
            "text": "Yo soy el Dr. Miguel \u00c1ngel Ibarra Estrada, trabajo para el Instituto Jalisciense de Cancerolog\u00eda, el Hospital Civil de Guadalajara, y el Consejo Nacional de Ciencia y Tecnolog\u00eda. Estamos investigando sobre el uso de un m\u00e9todo no ventilatorio considerado actualmente como \"no convencional\" en pacientes con S\u00edndrome de Falla Respiratoria Aguda asociada a COVID-19, una entidad muy com\u00fan a nivel global actualmente. Le voy a dar informaci\u00f3n e invitarle a participar de esta investigaci\u00f3n. No tiene que decidir hoy si participar o no en esta investigaci\u00f3n. Antes de decidirse, puede hablar con alguien con quien se sienta c\u00f3modo sobre la investigaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introducci\u00f3n"
        },
        {
            "text": "Puede que haya algunas palabras que no entienda. Por favor, interr\u00fampame seg\u00fan le informo para darme tiempo a explicarle. Si tiene preguntas m\u00e1s tarde, puede preguntarme a mi, a otros doctores que investigan o a miembros del equipo m\u00e9dico.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introducci\u00f3n"
        },
        {
            "text": "a v e d a d asociado a una alteraci\u00f3n severa en los pulmones, que no permite que el ox\u00edgeno que se respira se traslade a la sangre. A pesar de las mejoras en el tratamiento especializado en las \u00faltimas d\u00e9cadas, aproximadamente 6-8 de cada 10 de los pacientes que son intubados, fallecen. Existe un modo no ventilatorio ya conocido, aunque poco utilizado en nuestro pa\u00eds, que podr\u00eda favorecer el mejoramiento de este estado de gravedad y potencialmente evitar la intubaci\u00f3n y que usted o su familiar tengan que recibir soporte ventilatorio mec\u00e1nico. El determinar con certeza el beneficio potencial de este m\u00e9todo es la raz\u00f3n por la que hacemos este estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E l S \u00ed n d r o m e d e D i f i c u l t a d R e s p i r a t o r i a A g u d a a s o c i a d a a C O V I D -1 9 e s u n e s t a d o d e g r"
        },
        {
            "text": "Esta investigaci\u00f3n incluir\u00e1 el manejo no ventilatorio llamado \"pronaci\u00f3n\", que consiste en voltearlo a usted o a su familiar 'boca abajo' la mayor parte del d\u00eda seg\u00fan lo tolere, cuando el equipo m\u00e9dico identifique que se encuentra en riesgo alto de requerir ventilaci\u00f3n mec\u00e1nica, y se llevar\u00e1 a cabo desde la identificaci\u00f3n de la alteraci\u00f3n pulmonar moderada/severa hasta la resoluci\u00f3n o desenlace final. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tipo de Intervenci\u00f3n de Investigaci\u00f3n"
        },
        {
            "text": "Su participaci\u00f3n (o la de su familiar) en esta investigaci\u00f3n es totalmente voluntaria. Usted puede elegir participar o no hacerlo. Tanto si elige participar o no, continuar\u00e1n todos los servicios que reciba en esta unidad y nada cambiar\u00e1. Usted puede cambiar de idea m\u00e1s tarde y dejar de participar a\u00fan cuando haya aceptado antes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participaci\u00f3n Voluntaria"
        },
        {
            "text": "El m\u00e9todo de pronaci\u00f3n es un m\u00e9todo aplicado desde hace m\u00e1s de 20 a\u00f1os a los pacientes con s\u00edndrome de dificultad respiratoria aguda. Se ha probado antes con personas con este tipo de enfermedad pulmonar, aunque solo en los que ya estuvieron recibiendo ventilaci\u00f3n mec\u00e1nica, demostrando resultados favorables al grado de volverse una recomendaci\u00f3n ampliamente aceptada en todo el mundo. Ahora queremos probar este m\u00e9todo en personas de nuestro entorno con insuficiencia respiratoria asociada a COVID-19 pero desde antes de ser intubados. A esta investigaci\u00f3n se la denomina \"Fase 2\" de un ensayo cl\u00ednico.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informaci\u00f3n sobre el m\u00e9todo de investigaci\u00f3n"
        },
        {
            "text": "Debe saber que aunque cualquier tipo de manejo de pacientes graves tiene efectos adversos potenciales, de este m\u00e9todo en particular solo se han reportado eventualidades no serias como ulceraciones o edema en cara, o dolor transitorio en brazos o espalda.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informaci\u00f3n sobre el m\u00e9todo de investigaci\u00f3n"
        },
        {
            "text": "Algunos de los participantes en la investigaci\u00f3n no ser\u00e1n tratados con dicho m\u00e9todo. En su lugar, recibir\u00e1n el manejo est\u00e1ndar que es b\u00e1sicamente el recomendados actualmente seg\u00fan autoridades internacionales. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informaci\u00f3n sobre el m\u00e9todo de investigaci\u00f3n"
        },
        {
            "text": "Como ya se mencion\u00f3, este m\u00e9todo ventilatorio no tiene efectos adversos serios. Es posible que pueda tambi\u00e9n causar problemas que a\u00fan no conocemos. Sin embargo, le haremos un seguimiento y mantendremos un registro de cualquier efecto no deseado o cualquier problema. Puede que usemos otros m\u00e9todos para disminuir los s\u00edntomas de los efectos secundarios o reacciones. O puede que dejemos de usar el m\u00e9todo experimental. Si esto es necesario, lo discutiremos con usted y siempre se le consultar\u00e1 antes de continuar con el pr\u00f3ximo paso.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Efectos Secundarios"
        },
        {
            "text": "S i u s t e d o s u f a m i l i a r p a r t i c i p a e n e s t a i n v e s t i g a c i \u00f3 n , n o s e g a r a n t i z a q u e o b t e n g a n i n g \u00fa n beneficio personal. Puede que no halla beneficio para usted, pero es probable que su participaci\u00f3n nos ayude a encontrar una respuesta a la pregunta de investigaci\u00f3n. Puede que no haya beneficio para la sociedad en la fase actual de la investigaci\u00f3n, pero es probable que generaciones futuras se beneficien. e q u e s i otros miembros de la comunidad saben que usted participa, puede que le hagan preguntas. Nosotros no compartiremos la identidad de aquellos que participen en la investigaci\u00f3n. La informaci\u00f3n que recojamos por este proyecto de investigaci\u00f3n se mantendr\u00e1 confidencial. La informaci\u00f3n acerca de usted o su familiar que se recoger\u00e1 durante la investigaci\u00f3n ser\u00e1 puesta fuera de alcance y nadie adem\u00e1s de los investigadores tendr\u00e1n acceso a ella. Cualquier informaci\u00f3n acerca de usted tendr\u00e1 un n\u00famero en lugar de su nombre. Solo los investigadores sabr\u00e1n cual es su n\u00famero y se mantendr\u00e1 la informaci\u00f3n encerrada en cabina con llave. No ser\u00e1 compartida ni entregada a nadie.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Beneficios"
        },
        {
            "text": "U s t e d n o t i e n e p o r q u e p a r t i c i p a r e n e s t a i n v e s t i g a c i \u00f3 n s i n o d e s e a h a c e r l o , y e l n e g a r s e a p a r t i c i p a r no le afectar\u00e1 en ninguna forma a que sea tratado en esta unidad. Usted a\u00fan tendr\u00e1 todos los beneficios que de otra forma tendr\u00eda. Puede dejar de participar en la investigaci\u00f3n en cualquier momento que desee sin perder sus derechos como paciente aqu\u00ed. Su tratamiento no ser\u00e1 afectado en ninguna forma. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Derecho a negarse o retirarse"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan",
            "authors": [
                {
                    "first": "C H",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Y W",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "X L",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "L R",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "J Z",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Y H",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Lancet",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Acute respiratory distress syndrome: the Berlin Definition",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Caldwell",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "JAMA",
            "volume": "307",
            "issn": "23",
            "pages": "2526--2559",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "COVID-19 Pneumonia: ARDS or Not? Critical care",
            "authors": [
                {
                    "first": "L G",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "D C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Care for Critically Ill Patients With COVID-19",
            "authors": [
                {
                    "first": "S M",
                    "middle": [],
                    "last": "Cd G",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Ra F",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "JAMA",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Prone positioning in severe acute respiratory distress syndrome",
            "authors": [],
            "year": 2013,
            "venue": "N Engl J Med",
            "volume": "368",
            "issn": "23",
            "pages": "2159--68",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Prone Positioning Improves Oxygenation in Spontaneously Breathing Nonintubated Patients With Hypoxemic Acute Respiratory Failure: A Retrospective Study",
            "authors": [
                {
                    "first": "V S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "G G",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "L C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "A Z",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "S I",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "A L",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Journal of critical care",
            "volume": "30",
            "issn": "6",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Patients with immediate need of invasive mechanical ventilation (altered mental status, fatigue) -Vasopressor requirement to maintain median arterial pressure >65 mmHg -Contraindications for prone positioning therapy (recent abdominal or thoracic surgery or trauma, facial, pelvic or spine fracture, untreated pneumothorax.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "DP, A S, P F, et al. Feasibility and Physiological Effects of Prone Positioning in Non-Intubated Patients With Acute Respiratory Failure Due to COVID-19 (PRON-COVID): A Prospective Cohort Study. The Lancet Respiratory medicine. 2020. 11. W A, MH M, YM A, M L, MN G, E F, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults With Coronavirus Disease 2019 (COVID-19). Intensive care medicine. 2020. 12. RAA, ADK, TMC, et al. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia 2020 Oct;75(10):1340-1349.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "a COVID-19 para participar en la investigaci\u00f3n sobre un m\u00e9todo no ventilatorio alternativo con potencial para mejorar su pron\u00f3stico.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "los participantes en dos grupos. Los grupos son seleccionados por azar, al igual como lanzar una moneda al aire.Los trabajadores de la salud le estar\u00e1n observando cuidadosamente y tambi\u00e9n a los otros participantes durante el estudio. Si llega a preocuparnos lo que la pronaci\u00f3n hace, podremos realizar cambios inmediatos en el manejo. Si existe algo que le preocupe o que le moleste sobre la investigaci\u00f3n, por favor hable conmigo o con alguno de los otros investigadores. Usted recibir\u00e1 el resto del tratamiento de su condici\u00f3n bajo pautas internacionales. Civil Fray Antonio Alcalde y hasta su egreso.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Qui\u00e9n Contactar S i t i e n e c u a l q u i e r p r e g u n t a p u e d e h a c e r l a s a h o r a o m \u00e1 s t a r d e , i n c l u s o d e s p u \u00e9 s d e h a b e r s e iniciado el estudio. Si desea hacer preguntas m\u00e1s tarde, puede contactar cualquiera de las siguientes personas: Miguel \u00c1ngel Ibarra Estrada, Guadalupe Aguirre Avalos, Quetzalc\u00f3atl Ch\u00e1vez Pe\u00f1a (Hospital Civil Fray Antonio Alcalde, Unidad de Terapia Intensiva).",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Escalada de terapiaTiempo a VNI (si se utiliz\u00f3)",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "He sido invitado a participar en la investigaci\u00f3n de un m\u00e9todo no ventilatorio relativamente nuevo llamado pronaci\u00f3n, para el manejo del S\u00edndrome de Dificultad Respiratoria Aguda asociada a COVID-19. He sido informado de que los riesgos asociados directamente al manejo son m\u00ednimos. Se me ha proporcionado el nombre de uno o m\u00e1s investigadores que pueden ser contactados en caso de requerir mayor informaci\u00f3n.He le\u00eddo la informaci\u00f3n proporcionada o me ha sido le\u00edda. He tenido la oportunidad de preguntar sobre ella y se me han contestado satisfactoriamente las preguntas que he realizado. Consiento voluntariamente participar (o que mi familiar participe) en esta investigaci\u00f3n, y entiendo que tengo el derecho de retirarme de la investigaci\u00f3n en cualquier momento sin que afecte en ninguna manera mi cuidado m\u00e9dico (o de mi familiar). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Formulario de Consentimiento"
        }
    ]
}